H. Awuoche 1 , G.Kiringa 1 , V. Nduba 1 , E. Mitchell 2 1 KEMRI/CDC Research and Public Health Collaboration 2 KNCV Dutch Tuberculosis Foundation XIX International AIDS Society Conference Walter E. Washington Convention Centre, Washington, D.C 22 nd -27 th July 2012.
H. Awuoche1, G.Kiringa1, V. Nduba1, E. Mitchell2
1 KEMRI/CDC Research and Public Health Collaboration
2KNCV Dutch Tuberculosis Foundation
XIX International AIDS Society Conference
Walter E. Washington Convention Centre, Washington, D.C
22nd-27th July 2012Cost Effectiveness of Two Transport Strategies for Retention of Young Mothers and Infants Enrolled in a TB Vaccine Trial
‘Research participants may be reimbursed for their transport and other expenses including lost earnings associated with their participation in research’ (CIOMS guidelines 2002)
Transport reimbursement caters for costs incurred by study participants when travelling for clinic visits.
It is a critical tool in subject retention and motivation to continued study participation.
Additionally, it increases access to health care in our settings where distance to health facilities impedes health seeking behavior, thereby reducing infant mortality
Using ethically approved rates, there’s risk of under-compensation
Despite under-compensation, retention rate was high but at a cost three times higher than directly reimbursing the participants.
Limitations: there is need to conduct formative studies to understand the views of potential participants on under compensation and the effects on study endpoints and retention
There is also need for continued dialogue between investigators and Ethical Committees
There is room for continued education of participants on research ethics and non monetary benefits of research participation